Malignant hypertension medical therapy: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Malignant hypertension}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References==...")
 
 
(8 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Malignant hypertension}}
{{Malignant hypertension}}
{{CMG}}


Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
==Overview==
The most commonly used intravenous drug is [[nitroprusside]]. An alternative for patients with renal insufficiency is intravenous [[fenoldopam]]. [[Labetalol]] is another common alternative, providing easy transition from IV to oral (PO) dosing. Beta-blockade can be accomplished intravenously with [[esmolol]] or [[metoprolol]]. [[Hydralazine]] is reserved for use in pregnant patients, while [[phentolamine]] is the drug of choice for a [[pheochromocytoma]] crisis. iv sodium nitroprusside should be used with caution as it can cause a rapid uncontrollable drop in blood pressure.
 
====Contraindicated medications====
 
{{MedCondContrAbs
 
|MedCond = Malignant hypertension|Warfarin|
 
}}


==References==
==References==

Latest revision as of 18:46, 5 September 2014

Malignant hypertension Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Malignant hypertension from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Malignant hypertension medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Malignant hypertension medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Malignant hypertension medical therapy

CDC on Malignant hypertension medical therapy

Malignant hypertension medical therapy in the news

Blogs on Malignant hypertension medical therapy

Directions to Hospitals Treating Malignant hypertension

Risk calculators and risk factors for Malignant hypertension medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

The most commonly used intravenous drug is nitroprusside. An alternative for patients with renal insufficiency is intravenous fenoldopam. Labetalol is another common alternative, providing easy transition from IV to oral (PO) dosing. Beta-blockade can be accomplished intravenously with esmolol or metoprolol. Hydralazine is reserved for use in pregnant patients, while phentolamine is the drug of choice for a pheochromocytoma crisis. iv sodium nitroprusside should be used with caution as it can cause a rapid uncontrollable drop in blood pressure.

Contraindicated medications

Malignant hypertension is considered an absolute contraindication to the use of the following medications:

References


Template:WikiDoc Sources